Monoclonal Antibodies It’s Production and Application- Review

Raghunathan .(2018). Monoclonal antibody an updated review in dentistry. International Journal of Current Research;Vol.10:72408-72412, DOI: 10.24941/ijcr.31949.08.2018.      

[2] Hongtai Jing1, Zhengtao Gao1, Sheng Xu4, Tao Shen, Zhangzhi Peng, Shwai He, Tao You, Shuang Ye6, , Wei Lin1, Siqi Sun. (2024). Accurate prediction of antibody function and structure using bio-inspired antibody language model. Briefings in Bioinformatics, 2024, 25(4), bbae245 189-194, DOI: https://doi.org/10.1093/bib/bbae402

[3]    Ahmed Elnaggar, Michael Heinzinger, Christian Dallago, Ghalia Rehawi, Yu Wang, Llion Jones, Tom Gibbs, Tamas Feher, Christoph Angerer, Martin Steinegger, Debsindhu Bhowmik, Burkhard Rost. (2021).Prottrans: toward understanding the language of life through self-supervised learning. IEEE Trans Pattern Anal Mach Intell;44(10):7112–27.

[4]     Lin Zhaoa , Qi Wub , Ruirui Songc and Zhenyu Yun Genetic Engineering Antibody: Principles and Application. IOP Conf. Series: Materials Science and Engineering 612, doi:10.1088/1757-899X/612/2/022045

 [5]       Pecetta S, Finco O,Seubert A.(2020). Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era”. Seminars in Immunology journal , 50:101427. DOI: 10.1016/j.smim.2020.101427

[6]  Buss N. A. P. S,Henderson S. J,  McFarlane M,ShentonJ. M, De Haan L(2012).Monoclonal antibody therapeutics: History and future”. Current Opinion in Pharmacology journal,Vol. 12(5): 615-622. DOI: 10.1016/j.coph.2012.08.001

 [7]       Chowdhury N, Sood N. K, Lal  S, Gupta K, Singla L. D. (2013).Development of some larval nematodes in experimental and natural animal hosts: An insight into development of pathological lesions vis-a-vis host-parasite interactions. The Scientific World Journal, 8 pages.  DOI: 10.1155/2013/162538

 [8]       Deb R, Chakraborty S, Veeregowda B, Verma A. K, Tiwari R. (2013).Monoclonal antibody and its use in the diagnosis of livestock diseases. Special Issue in Antibody Research,Vol. 4(4A): 50-62. DOI: 10.4236/abb.2013.44A008

[9]      Santos-Neto J. F, Oliveira F. O,  Hodel K. V. S,Fonseca L. M. S, Badaro R,  Machado B. A. S. (2021).Technological Advancements in Monoclonal Antibodies. The Scientific World Journal,  DOI: 10.1155/2021/6663708

 [10]     Pendley C, Schantz A, Wagner C. (2003).Immunogenicity of therapeutic monoclonal antibodies. Current Opinion in Molecular Therapeutics. 2003,Vol.5:172–179.

[11]      Chan S. K, Rahumatullah A, Lai J. Y,  Lim T. S. (2017).Naïve Human Antibody Libraries for Infectious Diseases Adv. Exp. Med. Biol J. 2017; DOI: 10.1007/978-3-319-72077-7_3

 [12]     Wu Y ,Li S, Du L , Wang  C, Zou P,B Hong B, Yuan M, Ren X, Tai W, Kong Y, Zhou C,  Lu L,Zhou X ,Jiang S , Ying T . (2017.).Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain IIIE. merging and Microbes Infections journal,Vol. 6:e89. DOI: 10.1038/emi.2015.74

 [13] Giuseppe P, Bruno C, Craig F, Victor S. Joo, and Laurent P.(2022). Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 21(9): 676–696. doi: 10.1038/s41573-022-00495-3

 [14]     Köhler  G and  Milstein C .(1975).Continuous cultures of fused cells secreting antibody of predefined specificity,Nature,  256:495–497,DOI: 10.1038/256495a0

 [15]     Pollack P and Groothuis J.R. .(2002).Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV” , Journal of infection and Chemotherapy,2002,ol.8:201–206.  DOI: 10.1007/s10156-002-0178-6

 [16]     Jong-Pyo K., Hanool Y., Eun-Jung K., Yun-Gon K., Chang-Soo.L, Byoung J., Byung-Gee K.,J Hee-Jin J.(2003). Generation of a novel monoclonal antibody against inflammatory biomarker S100A8 using hybridoma technology. 45(Suppl 1):1-12, DOI:10.1007/s10529-023-03364-0

[17]      Smith GP. (1985).Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface”,Science j , 228:13151317.  DOI: 10.1126/science.4001944

[18]      McCafferty J , Griffiths AD ,  Winter G, Chiswell DJ. (1990).Phage antibodies: filamentous phage displaying antibody variable domains”  Nature. Vol.348:552–554. DOI: 10.1038/348552a0

 [19]     Ledsgaard L , Kilstrup M ,  Karatt-Vellatt A, McCafferty J ,LaustsenA.H .(2018).Basics of Antibody Phage Display Technology Toxins(Basel)J.Vol.10:236. DOI: 10.3390/toxins10060236

[20]      Frenzel A., Schirrmann T., Hus M .(2016).Phage display-derived human antibodies in clinical development and therapy MAbs.,Vol.8:1177–1194, DOI: 10.1080/19420862.2016.1212149

[21]      Sandhya B, Shanshan L, Michael S, Hillary A V, Xueyong Z, Nurgun K, Robin B, Jessica A F, Stephen J K, Pavlo G, Iuliia G, Hannah L T, Adolfo G, Sheng L, Andrew B W, Ian A W, James E C.(2019) A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell. 2019 May 16;177(5):1136-1152.e18. DOI: 10.1016/j.cell.2019.04.011

 [22]     Sun Y., Ban B., Bradbury A.,  Ansari G.A., Blake D.A. (2016).Anal. Combining Yeast Display and Competitive FACS to Select Rare Hapten-Specific Clones from Recombinant Antibody Libraries Analaytical Chemistry, Vol.88:9181–9189. DOI: 10.1021/acs.analchem.6b02334

 [23]     Lipovsek D and  Pluckthun AJ. (2004).In-vitro protein evolution by ribosome display and mRNA display..Immunol Methods,  Vol.290:51–67.  DOI: 10.1016/j.jim.2004.04.008

 [24]     Atsumi Sakaguchi, Yoichiro Tanaka, Eiki Shoji, Teppei Takeshima, Rina Sakamaki, Takao Matsuba & Yasuyuki Kurihara.(2023). Rapid, simple, and effective strategy to produce monoclonal antibodies targeting protein structures using hybridoma technology. Journal of biological Engineering. Vol. ) 17:24 https://doi.org/10.1186/s13036-023-00345-9.

[25]      Perry S.T ,  Keogh E,  Morton M , Koudstaal W , Pascual G. (2019).Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations”.J Vix Exp, Vol.22:(150). DOI: 10.3791/59809

[26]      Guarner J, Hale GL (2019) Four human diseases with signifcant public health impact caused by mosquito-borne faviviruses: West Nile, Zika, dengue and yellow fever. Semin Diagn Pathol 36:170–176. https://doi.org/10.1053/j.semdp.2019.04.009

[27]      González-Fernández Á, Bermúdez Silva FJ, López-Hoyos M, Cobaleda C, Montoliu L, Del Val M, Leech K.(2020). Non-animal-derived monoclonal antibodies are not ready to substitute current hybridoma technology. Nature Meth. 17:1069–70. https://doi.org/10.1038/s41592-020-00977-5.

[28]      Corti D and Lanzavecchia A.. (2004).Broadly Neutralizing Antiviral Antibodies Annu. Rev. Immunol”.Nat Med J, Vol.31:705–742.  DOI: 10.1146/annurev-immunol-032712-095916

[29] Parray HA, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C, Kumar R. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020;85:106639. https://doi.org/10.1016/j.intimp.2020.106639.

[30]      Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021;19:159. https://doi.org/10.1186/s43141-021-00264-6.

 [31]     Jin Lu I, Tadas P, Kim T, Jeroen A, Michael N,  Jamie F, Michael R, Raymond W.S.(2014) IgG variable region and VH CDR3 diversity in unimmunized mice analyzed by massively parallel sequencing. Mol Immunol. Vol.57(2):274-83. DOI: 10.1016/j.molimm.2013.09.008

 [32]     Reddy S.T., Ge X., Miklos E., Hughes R.A. Hyun S, Kang H., Chrysostomou C., Hunicke S.P-., verson B.L., Tucker P.W., Ellington A.D., and Georgiou G.(2010).Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells Nat. BiotechnolVol.28:965–969 DOI: 10.1038/nbt.1673

 [33] Wang B., Kluwe C.A., Lungu O.L., DeKosky B.J.,  Kerr S.A., Johnson E.L., Tanno H., Lee C.H., Jung J., Rezigh A.B., Carroll S.M., Reyes A.N., Bentz J.R., Villanueva I., Altman A.L., Davey R..,A.,Ellington. D, Georgiou G. (2015).Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining”. Sci. Rep. Vol. 5:13926.  DOI: 10.1038/srep13926

[34]      Parola. C, Neumeier D., Reddy S.T. (2018).Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering.”. Immuonology . Vol.153:31–41. DOI: 10.1111/imm.12838

 [35]     Zhu. J, Ofek G., Yang Y., Zhang B., Louder M.K., Lu G., McKee K., Pancera. M, Skinner J., Zhang Z., Parks R., Eudailey J., Lloyd K.E., Blinn J., Alam S.M., Haynes B.F., Simek M., Burton D.R., Koff W.C. NISC Comparative Sequencing Program, Mullikin J.C,. Mascola J.R, Shapiro L., and Kwong P.D . (2013).Mining the antibodyome for HIV-1–neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains”  .Proc. Natl. Acad. Sci. U. S. A. 2013;Vol.110:6470–6475.  DOI: 10.1073/pnas.1219320110

[36]      Jiang Z , Xueling W, Baoshan Z, Krisha M, Sijy O, Cinque S, Tongqing Z, Joseph P; NISC Comparative Sequencing Program; James C, Peter D.K, John R, Lawrence S. (2013).De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts Proc. Natl. Acad. Sci. U. S. A. Vol.110(43):E4088-97. DOI: 10.1073/pnas.1306262110

 [37]     Tian. X,  Li. C, Huang A., Xia S., Lu S., Shi Z., Lu L., Jiang. S, Yang Z., Wu Y., Ying T. .(2020).Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect.  Vol.9:382–385.DOI: 10.1080/22221751.2020.1729069

 [38]     Sormanni P., Aprile F., Vendruscolo M. (2018).Third generation antibody discovery methods: in silico rational design.Chem. Soc. Rev..Vol.  47:9137–9157.  DOI: 10.1039/c8cs00523k

 [39]     Sushama R, Sadique Hussain M.D , Chandan M , Gurleen K . (2021).An Overview Of Monoclonal Antibodies And Their Therapeutic Applications. Nat. Volatiles & Essent. Oils, Vol.8(6): 4121-4130

[40]      Ruei-Min L,. Yu-Chyi H , Ju Liu J , Chi-Chiu L , Han-Zen T, Hsin-Jung L , Han-Chung W . (2020).Development of therapeutic antibodies for the treatment of diseases”. Journal of Biomedical Science , Vol;27:1. DOI: 10.1186/s12929-019-0592-z

 [41]     Dimitrov D.S nd Marks J.D .(2009).Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?. Methods in Molecular Biology.Vol.525:1-13.  DOI: 10.1007/978-1-59745-554-1_1

[42]      Castelli M.S, Mc Gonigle P, Hornby P.J. (2019).The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology Research & Perspectives; Vol.7(6). DOI: 10.1002/prp2.535

 [43]     Lim C.Y, Lee K.J, Oh D.B, and Ko K .(2015)Effect of the developmental stage and tissue position on the expression and glycosylation of recombinant glycoprotein GA733-FcK in transgenic plants, Frontiers in Plant Science, vol. 5, article 778, 11 pages.(52). DOI: 10.3389/fpls.2014.00778

[44]      Faye L, Landry Lerouge N.P, Gomord V, and Vezina L.(2021).La ´production de proteines ´ a usage biopharmaceutique dans les ` plantes, Medecine/Sciences SYNTHESE ´.vol. 17, no. 8-9, pp. 867– 877, (53). DOI:10.4267/10608/2021

[45]      Song I.C, Kim D.S, Kim M.K, Jamal A, Hwang K.A, and Ko K.(2015).Comparison of total soluble protein in various horticultural crops and evaluation of its quantification methods,” Horticulture, Environment, and Biotechnology. vol. 56, no. 1, pp. 123–129, (54). DOI:10.1007/s13580-015-0097-y

[46]      Ko K and Koprowski H.(2005). Plant biopharming of monoclonal antibodies,” Virus Research. vol. 111, no. 1, pp. 93–100, 2005.(16). doi: 10.1016/j.virusres.2005.03.016.

[47]      Ko K, Wei X, Crooks P.A, and Koprowski H, .(2004).Elimination of alkaloids from plant-derived human monoclonal antibody,” Journal of Immunological Methods, vol. 286, no. 1-2, pp. 79–85(55). DOI: 10.1016/j.jim.2003.11.015

 [48]     Fischer R, Stoger E, Schillberg S, Christou P, and Twyman R.M. .(2004).Plant-based production of biopharmaceuticals. Current Opinion in Plant Biology,vol. 7, no. 2, pp. 152–158, (57). DOI: 10.1016/j.pbi.2004.01.007

[49]      Faye L,  Boulaflous A, Benchabane M, Gomord V, and Michaud D.(2005).Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming,” Vaccine, Vol. 23, no. 15, pp. 1770–1778, (58). 2004- DOI: 10.1016/j.vaccine.2004.11.003

[50]      Rodolfo V , Leonardo G, Sigifredo P, José B, Biunayki R, Tatiana A, Otto M, Orlando H, William F, Merardo P, Vladimir L, Marbelis L, Yasser H, Cristina G, Lorely M, Olga G, Rafael S, Alfonso A, Déborah G, Rolando P,  Jorge L.V, Carlos B. (2003).Large-scale purification ´ of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants, Biochemical and Biophysical Research Communications,2003, Vol. 308, no. 1, pp. 94–100, (77).  DOI: 10.1016/s0006-291x(03)01335-4

 [51]     Ko K, Steplewski Z, Glogowska M, and Koprowski H . (2005)Inhibition of tumor growth by plant-derived mAb,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, no. 19, pp. 7026–7030, 2005.(30). DOI: 10.1073/pnas.0502533102

[52]      Margarita T, Blanca L,  Sabine L.R, Immaculada L.T, Miriam B, Pau M, Ann W.P, Markku S, Peter B Heifetz, Dolors Ludevid M . .(2009).Eukaryotic protein production in designed storage organelles,” BMC Biology, Vol. 7, article 5, (82).  DOI: 10.1186/1741-7007-7-5

[53]      MacEwan S.R, Hassouneh W, and Chilkoti A. , (2014).Non-chromatographic purification of recombinant elastin-like polypeptides and their fusions with peptides and proteins from Escherichia coli,” Journal of Visualized Experiments, no. 88, Article ID e51583, (83) DOI: 10.3791/51583

 [54]     Joensuu J.J, Conley A.J, Linder M.B, and Menassa R.(2020).Biosep aration of recombinant proteins from plant extract with hydro phobin fusion technology,” Methods in Molecular Biology, vol. 824, pp. 527–534.2020.  DOI: 10.1007/978-1-61779-433-9_28

[55]    David Z  and Louis W .(2020). Monoclonal Antibodies in Cancer Therapy”.   Antibodies           j, 9(3), 34; DOI: 10.3390/antib9030034

 [56]     Ralf L, Tobias R, Roman K, Patrick H, Susanne M, Benno R, Matthias F, Oliver T, Grit L, Doris Rau, Evelyne S, Ines H, Andreas W, Thomas U, Patrick A.B, Peter K.(2010).T Cell-Engaging BiTE Antibodies Specific for EGFR Potently Eliminate KRAS- and BRAF-Mutated Colorectal Cancer Cells”. Proc. Natl. Acad. Sci. USA , 107, 12605–12610. DOI: 10.1073/pnas.1000976107.

[57]      Hagop  K, Anthony S, Nicola G, Adele K.F , Andre C.S, Josep-Maria R, Andrew W, Hervé D, Robin F, Renato B, Önder A, Migue A.S, Julie B, Fatih D, Ewa L.M, Alessandro R, Xavier T, . Heinz-August H, Monika B, Wolfram K, Brent L.W,  Alex F,  Dirk N , Christopher H, Zachary Z, Max S.T . (2017).Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia”. N. Engl. J. Med. 376, 836–847. DOI: 10.1056/NEJMoa1609783

[58]      Redman J.M, Hill E.M, AlDeghaither D, Weiner L.M.(2015).Mechanisms of Action of Therapeutic Antibodies for Cancer”. Mol. Immunol.Vol.67, 28–45. DOI: 10.1016/j.molimm.2015.04.002

 [59]     Sushama R, Md Sadique H, Chandan M, Gurleen K..(2021).An Overview Of Monoclonal Antibodies And Their Therapeutic Applications”. Nat. Volatiles & Essent. Oils; Vol.8(6): 4121-4130.

[60]      Tigabu D, Endale B and Haben F.(2020).Monoclonal Antibody and its Diagnostic Application- Review .BioMedical J., V. 30- Issue 4. DOI: 10.26717/BJSTR.2020.30.004997